Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M
Department of Gastroenterology, Osaka City General Hospital,Osaka, Japan.
J Gastroenterol Hepatol. 2001 Dec;16(12):1378-83. doi: 10.1046/j.1440-1746.2001.02643.x.
The Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) has been reported to be a highly useful marker for hepatocellular carcinoma (HCC) compared with a conventional serum AFP concentration, which allows earlier detection of HCC compared with using other imaging modalities and predicting prognosis after therapy. A collaborative prospective study involving nine Japanese hospitals was conducted to analyze the relationships between the tumor characteristics of a HCC patient and the percentage of AFP-L3/AFP total at the initial detection.
Between 1 October 1996 and 30 September 1997, a total of 388 patients with newly diagnosed HCC were registered.
The cut-off level of the percentage of AFP-L3 was altered from 15 to 10%. The AFP-L3-positive HCC patients demonstrated the characteristics of having an advanced tumor, such as the number of tumors, maximum diameter, tumor spread, portal vein invasion, tumor stage, and tumor classification. With the conventional cut-off level of 15% of the percentage of AFP-L3, the malignant characteristics were more definite than that of 10%. However, no significant differences of serum AFP concentration were observed for malignant characteristics such as maximum diameter and histopathological grading.
Serum AFP concentration does not reveal a malignancy of HCC, however, the AFP-L3-positive HCC has biologically malignant characteristics, especially portal vein invasion and lower tumor classification, and is an advanced tumor regardless of small tumor size and lower serum AFP concentration. As AFP-L3 shows the tumor characteristics, its presence should be an important factor in the determination of therapy and prognosis of patients.
据报道,与传统血清甲胎蛋白(AFP)浓度相比,甲胎蛋白的刀豆球蛋白A反应性部分(AFP-L3)是肝细胞癌(HCC)的一种非常有用的标志物,与使用其他成像方式相比,它能更早地检测出HCC,并预测治疗后的预后。一项涉及9家日本医院的合作前瞻性研究分析了HCC患者的肿瘤特征与初次检测时AFP-L3/总AFP百分比之间的关系。
在1996年10月1日至1997年9月30日期间,共登记了388例新诊断的HCC患者。
AFP-L3百分比的临界值从15%改为10%。AFP-L3阳性的HCC患者表现出肿瘤进展的特征,如肿瘤数量、最大直径、肿瘤扩散、门静脉侵犯、肿瘤分期和肿瘤分级。以AFP-L3百分比15%的传统临界值来看,恶性特征比10%时更明确。然而,对于最大直径和组织病理学分级等恶性特征,血清AFP浓度未观察到显著差异。
血清AFP浓度不能揭示HCC的恶性程度,然而,AFP-L3阳性的HCC具有生物学上的恶性特征,尤其是门静脉侵犯和较低的肿瘤分级,并且无论肿瘤大小和血清AFP浓度如何,都是进展期肿瘤。由于AFP-L3显示了肿瘤特征,其存在应是确定患者治疗和预后的一个重要因素。